A panel of lymphoma experts discuss several novel agents for relapsed/ refractory diffuse large B-cell lymphoma, some of which have been recently approved.
Christina T. Loguidice
Advertisement
Articles by Christina T. Loguidice
During a recent OncLive Peer Exchange®, a panel of hematologic cancer experts discussed several novel treatments that are changing the relapsed/refractory mantle cell lymphoma treatment landscape, including Bruton tyrosine kinase (BTK) inhibitors, BTK combinations, and chimeric antigen receptor T-cell therapy.
Advertisement
Latest Updated Articles
MCL Treatments Step Away From Chemotherapy, Closer to a CurePublished: April 24th 2020 | Updated:
Making Progress Against Relapsed/ Refractory DLBCL Without CAR TPublished: November 3rd 2020 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Around the Helix: Cell and Gene Therapy Company Updates – October 29, 2025
2
Intellia Puts Phase 3 Trials for Transthyretin Amyloidosis Gene Editing Therapy Nex-Z on Hold Following Grade 4 Liver AE
3
Quarter Century Update: What Lessons Should Guide the Next Generation of Developers and Regulators?
4
Quarter Century Update: Future Predictions for the Field
5
